Xu Feng

Dr. Xu Feng


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
XFXu Feng
Xu Feng
ATAnthony Tubbs
Anthony Tubbs
CZChunchao Zhang
Chunchao Zhang
MTMengfan Tang
Mengfan Tang
SSSriram Sridharan
Sriram Sridharan
JCJunjie Chen
Junjie Chen

7 December 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
CWChao Wang
Chao Wang
GWGang Wang
Gang Wang
XFXu Feng
Xu Feng
PSPeter Shepherd
Peter Shepherd
JZJie Zhang
Jie Zhang
JCJunjie Chen
Junjie Chen

26 July 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ZCZhen Chen
Zhen Chen
CWChao Wang
Chao Wang
XFXu Feng
Xu Feng
LNLitong Nie
Litong Nie
MTMengfan Tang
Mengfan Tang
JCJunjie Chen
Junjie Chen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

22 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHuimin Zhang
Huimin Zhang
YXYun Xiong
Yun Xiong
DSDan Su
Dan Su
CWChao Wang
Chao Wang
MSMrinal Srivastava
Mrinal Srivastava
JCJunjie Chen
Junjie Chen
Anticancer drugs, such as camptothecin (CPT), trap topoisomerase I (TOP1) on DNA and form TOP1 cleavage complexes (TOP1cc). Alternative repair pathways have been suggested in the repair of TOP1cc. However, how these pathways work with TDP1, a key repair enzyme that specifically hydrolyze the covalent bond between TOP1 catalytic tyrosine and the 3’-end of DNA and contribute to the repair of TOP1cc is poorly understood. Here, using unbiased whole-genome CRISPR screens and generation of co-deficient cells with TDP1 and other genes, we demonstrate that MUS81 is an important factor that mediates the generation of excess double-strand breaks (DSBs) in TDP1 KO cells. APEX1/2 are synthetic lethal with TDP1. However, deficiency of APEX1/2 does not reduce DSB formation in TDP1 KO cells. Together, our data suggest that TOP1cc can be either resolved directly by TDP1 or be converted into DSBs and repaired further by the Homologous Recombination (HR) pathway.

1 March 2020 in DNA Repair
Verified
Journal Article
Closed access
DSDan Su
Dan Su
XFXu Feng
Xu Feng
MCMedina Colic
Medina Colic
YWYunfei Wang
Yunfei Wang
CZChunchao Zhang
Chunchao Zhang
JCJunjie Chen
Junjie Chen

13 May 2022 in Science Advances
Verified
Journal Article
Open access
XFXu Feng
Xu Feng
MTMengfan Tang
Mengfan Tang
MDMerve Dede
Merve Dede
DSDan Su
Dan Su
GPGuangsheng Pei
Guangsheng Pei
JCJunjie Chen
Junjie Chen
Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However, tumor suppressors cannot be directly targeted because of their loss of function. To uncover specific vulnerabilities for cells with deficiency in any given tumor suppressor(s), we performed genome-scale CRISPR loss-of-function screens using a panel of isogenic knockout cells we generated for 12 common tumor suppressors. Here, we provide a comprehensive and comparative dataset for genetic interactions between the whole-genome protein-coding genes and a panel of tumor suppressor genes, which allows us to uncover known and new high-confidence synthetic lethal interactions. Mining this dataset, we uncover essential paralog gene pairs, which could be a common mechanism for interpreting synthetic lethality. Moreover, we propose that some tumor suppressors could be targeted to suppress proliferation of cells with deficiency in other tumor suppressors. This dataset provides valuable information that can be further exploited for targeted cancer therapy.